12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ABT-333: Phase III started

Abbott, which markets Norvir ritonavir, has exclusive rights to ABT-450, an oral HCV NS3/4A protease inhibitor, from Enanta Pharmaceuticals Inc. (Cambridge, Mass.) (see BioCentury, Dec. 18, 2006). Abbott's ABT-267 is an HCV NS5A protein inhibitor, while ABT-333 is...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >